U.S. Markets close in 46 mins

Biogen Stock Is Slipping Because Investors Don’t Buy Its News on Lou Gehrig’s Disease

Josh Nathan-Kazis

In a webcast, the company outlined a strategy that focuses in the near term on rarer forms of amyotrophic lateral sclerosis, commonly known as Lou Gehrig’s disease.